Bipolar Disorder, previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed).
The ultimate goal of Bipolar Depression treatment is to achieve as high as possible a level of psychosocial function and health-related quality of life. BD is a highly recurrent disorder and sometimes medication needs to continue even if the patient feels well.
The treatment has two phases: the acute phase and the maintenance phase. Acute-phase treatment is focused on the management of acute mood episodes (manic, hypomanic, or depressive). Maintenance-phase treatment is focused on preventing recurrences of acute episodes. Each phase is associated with specific treatment needs, and available pharmacotherapies have shown differential effectiveness according to the illness phase.
Most commonly mood stabilizers, antipsychotics, antidepressants, antianxiety medications, and psychotherapy is used. In the United States, only four medications are approved for acute treatment of depressive episodes in the context of bipolar disorder: Symbyax (olanzapine-fluoxetine combination), Seroquel and Seroquel XR (quetiapine), Latuda (lurasidone), and Vraylar (cariprazine). Although older medications such as lithium also have modest effects in acute bipolar depression.
Bipolar Depression Market Insight
Bipolar Depression market size in 7MM in 2017 was USD 762.83 million
Bipolar Depression Market Drivers
- Novel insights into disease
- Improvement in treatment over the years
- Increasing adherence to treatment
- Increase in awareness and advancements in the technology
Bipolar Depression Market Barriers
- Delay in diagnosis
- Unrecognized and inappropriate treatment
- Neglects of quality of life, burden, and economic issues
- Unsatisfactory design of randomized controlled trials
- Lack of Knowledge to differentiate between unipolar and bipolar depression
1. Key Insights
2. Executive Summary of Bipolar Depression
3. Competitive Intelligence Analysis for Bipolar Depression
4. Bipolar Depression: Market Overview at a Glance
4.1. Bipolar Depression Total Market Share (%) Distribution in 2017
4.2. Bipolar Depression Total Market Share (%) Distribution in 2030
5. Bipolar Depression: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Bipolar Depression Pathophysiology
5.4. Bipolar Depression Risk Factors
5.5. Bipolar Depression Diagnosis
6. Patient Journey
7. Bipolar Depression Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Bipolar Depression Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Bipolar Depression Epidemiology
7.4.1. Bipolar Depression Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Bipolar Depression Epidemiology
7.5.1.1. Bipolar Depression Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Bipolar Depression Epidemiology
7.5.2.1. Bipolar Depression Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Bipolar Depression Epidemiology
7.5.3.1. Bipolar Depression Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Bipolar Depression Epidemiology
7.5.4.1. Bipolar Depression Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Bipolar Depression Epidemiology
7.5.5.1. Bipolar Depression Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Bipolar Depression Epidemiology
7.5.6.1. Bipolar Depression Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Bipolar Depression Treatment and Management
8.2. Bipolar Depression Treatment Algorithm
9. Bipolar Depression Unmet Needs
10. Key Endpoints of Bipolar Depression Treatment
11. Bipolar Depression Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Bipolar Depression Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Bipolar Depression: Seven Major Market Analysis
13.1. Key Findings
13.2. Bipolar Depression Market Size in 7MM
13.3. Bipolar Depression Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Bipolar Depression Market Size
15.1.1. Bipolar Depression Total Market Size in the United States
15.1.2. Bipolar Depression Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Bipolar Depression Market Size
15.3.1. Bipolar Depression Total Market Size in Germany
15.3.2. Bipolar Depression Market Size by Therapies in Germany
15.4. France Bipolar Depression Market Size
15.4.1. Bipolar Depression Total Market Size in France
15.4.2. Bipolar Depression Market Size by Therapies in France
15.5. Italy Bipolar Depression Market Size
15.5.1. Bipolar Depression Total Market Size in Italy
15.5.2. Bipolar Depression Market Size by Therapies in Italy
15.6. Spain Bipolar Depression Market Size
15.6.1. Bipolar Depression Total Market Size in Spain
15.6.2. Bipolar Depression Market Size by Therapies in Spain
15.7. United Kingdom Bipolar Depression Market Size
15.7.1. Bipolar Depression Total Market Size in the United Kingdom
15.7.2. Bipolar Depression Market Size by Therapies in the United Kingdom
15.8. Japan Bipolar Depression Market Outlook
15.8.1. Japan Market Size
15.8.2. Bipolar Depression Total Market Size in Japan
15.8.3. Bipolar Depression Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Bipolar Depression
17. KOL Views
18. Bipolar Depression Market Drivers
19. Bipolar Depression Market Barriers
20. Appendix
20.1. Bibliography
20.2. Bipolar Depression Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/